Skip to main content

Table 2 Biodistribution data of AAZTA-MG labelled with different radiometals 1 h p.i. in different mouse models

From: Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue

 

111In-AAZTA-MG

68Ga-AAZTA-MG

177Lu-AAZTA-MG

68Ga-AAZTA-MG

CCK+/− BALB/c nude mice

CCK+/− BALB/c nude mice

BALB/c nude mice

BALB/c nude mice

Blood

0.14 ± 0.03

0.38 ± 0.07

0.10 ± 0.09

2.90 ± 1.39

Spleen

0.14 ± 0.02

0.13 ± 0.01

0.11 ± 0.04

0.91 ± 0.34

Pancreas

0.13 ± 0.03

0.14 ± 0.02

0.12 ± 0.04

0.68 ± 0.28

Stomach

0.61 ± 0.11

0.47 ± 0.03

1.18 ± 0.13

0.95 ± 0.22

Intestine

8.62 ± 1.24

0.61 ± 0.08

19.14 ± 3.40

2.43 ± 0.32

Kidneys

1.79 ± 0.32

2.51 ± 0.66

1.39 ± 0.73

3.37 ± 0.43

Liver

2.46 ± 0.96

0.42 ± 0.07

3.05 ± 1.31

1.48 ± 0.26

Heart

0.12 ± 0.09

0.15 ± 0.04

0.07 ± 0.06

0.88 ± 0.32

Lung

0.21 ± 0.06

0.33 ± 0.07

0.14 ± 0.05

1.59 ± 0.47

Muscle

0.15 ± 0.18

0.07 ± 0.03

0.10 ± 0.17

0.36 ± 0.23

Femur

0.20 ± 0.11

0.11 ± 0.02

0.21 ± 0.18

0.74 ± 0.42

CCK2+ tumour (left flank)

1.74 ± 0.80

1.51 ± 0.53

  

CCK2− tumour (right flank)

0.33 ± 0.11

0.44 ± 0.06

  
  1. Data are shown as %ID/g (mean ± SD, n = 4)